Currently, there are several phase 1–3 clinical trials ongoing in MPN that extend beyond the scope of this review, but they include histone deacetylase (HDAC) inhibitors, modulators of cellular apoptosis such as navitoclax and BH3-mimetics, monoclonal antibodies such as tagraxofusp, hypomethylating agents, and combination therapies such as ruxolitinib and lenalidomide [12,212,213]. This evidence concerns the gene HDAC9 and myeloproliferative neoplasm.